Latest News

(UroToday.com) Nivolumab (anti-PD-1 antibody) and cabozantinib (tyrosine kinase inhibitor of MET, VEGFR, AXL, and others) each have single-agent activity in advanced renal cell carcinoma based on the CABOSUN, METEOR and CheckMate 025 studies. A recent phase 1 study in advanced genitourinary malignancies supported the activity and relative safety of combining these two drugs, leading to the […]

(UroToday.com) Targeted therapy has significantly changed the treatment landscape for renal cell carcinoma, and more recently, immuno-oncology–based combinations have also made a significant impact. Treatment choice in advanced renal cell carcinoma (aRCC) is informed by patient risk, as measured by the validated International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model. This model categorizes patients […]

(UroToday.com) The diagnosis of testicular cancer is associated with a long-term cumulative incidence of contralateral testicular cancer of 1.9-3.9% over a 15-20-year time span. While it has been hypothesized that patients who receive platinum chemotherapy as part of the management of their testicular cancer have a lower incidence of contralateral testicular cancer, data to answer this […]

(UroToday.com) Penile cancer is a rare genitourinary malignancy that is often associated with HPV infection. HPV infection results in the expression of the viral protein E7, which is capable of inhibiting the cell cycle proteins Rb and p21, leading to an accumulation of the p16 protein. Expression of p16 in penile cancer is associated with a […]

(UroToday.com) The POLE gene is one of the components of DNA polymerase epsilon, which is responsible for the replication of the leading DNA strand. POLE contains a DNA polymerase domain, as well as an exonuclease domain responsible for proofreading replication errors.

(UroToday.com) Following the presentations from Dr. de Bono and Dr. Joaquin Mateo of the data from IPATential150 and PROfound, respectively, Dr. Henrik Grönberg provided an invited discussion of these data.

(UroToday.com) There has been a rapid change in the past few years for patients with advanced prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). It was in this disease space that change first began in earnest with the introduction of docetaxel on the basis of TAX-327. Subsequently, both abiraterone acetate (COU-301 and COU-302) and enzalutamide (AFFIRM […]

(UroToday.com) In 2016, Pritchard and colleagues reported that mutations in DNA-damage repair genes, particularly homologous recombination repair genes, were relatively common among patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This opened the potential for targeted therapy: poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors lead to an accumulation of DNA single-stranded breaks which have particularly profound clinical […]

(UroToday.com) The KEYNOTE-052 trial showed that pembrolizumab monotherapy has durable antitumor activity as first-line therapy in cisplatin-ineligible patients with locally advanced unresectable or metastatic urothelial carcinoma (UC)1.  Moreover, pembrolizumab has also shown durable activity as 2nd line therapy in patients with platinum-refractory advanced UC in the KEYNOTE-045 trial2.

(UroToday.com) Pazopanib is a multi-tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α and β), fibroblast growth factor receptors (FGFR -1 and -3), cytokine receptor (Kit),interleukin-2 receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms).1